Immunology & Rheumatology Clinical Trials

Statistical methods in immunology & rheumatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All immunology & rheumatology trials

1,062 results

• Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes: primary endpoint results,…Phase 2Results postedn = 31NCT03399773
• INROADSIndependent statistical analysis of A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 54NCT01199939
• INSPIREIndependent statistical analysis of Alcohol Pharmacotherapy for HIV+ Prisoners: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01077310).Phase NAResults postedn = 100NCT01077310
• inTandem3Complete statistical analysis of the phase 3 inTandem3 trial of sotagliflozin in patients with type 1 diabetes and inadequate glycemic control with insulin therapy alone, including trial design, endpoints, statistical methodology, results,…Phase 3Results postedn = 1,405NCT02531035
• Investigating Racial Differences in Diet Benefits for Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of Investigating Racial Differences in Diet Benefits for Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04343716).Phase NAResults postedn = 19NCT04343716
• Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 60NCT04850846
• Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma: Complete Statistical AnalysisIndependent statistical analysis of Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With…Phase 2Results postedn = 37NCT00557440
• IOPAIndependent statistical analysis of A Study for Patients With Diabetes Mellitus (IOPA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00420095).Phase 4Results postedn = 117NCT00420095
• Ipilimumab and Local Radiation for Selected Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Ipilimumab and Local Radiation for Selected Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01769222).Phase 1Results postedn = 3NCT01769222
• IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?: Complete Statistical AnalysisIndependent statistical analysis of IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 40NCT02625428
• Islet Transplantation for Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Islet Transplantation for Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00014911).Phase 2Results postedn = 36NCT00014911
• ITPIndependent statistical analysis of Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00699140).Phase 3Results postedn = 18NCT00699140
• iTransition Development: Complete Statistical AnalysisIndependent statistical analysis of iTransition Development: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04383223).Phase NAResults postedn = 78NCT04383223
• Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib: Complete Statistical AnalysisIndependent statistical analysis of Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 165NCT01415882
• IXORA-RIndependent statistical analysis of A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 1,027NCT03573323
• JADE TEENIndependent statistical analysis of JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 287NCT03796676
• JUNGLEIndependent statistical analysis of Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 209NCT03518060
• KALMARIndependent statistical analysis of Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01068873).Phase 4Results postedn = 1NCT01068873
• Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.: Complete Statistical AnalysisIndependent statistical analysis of Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 144NCT00769886
• KPL-301 for Subjects With Giant Cell Arteritis: Complete Statistical AnalysisIndependent statistical analysis of KPL-301 for Subjects With Giant Cell Arteritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03827018).Phase 2Results postedn = 70NCT03827018
• LAL1610Independent statistical analysis of Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 35NCT01462253
• LASORIndependent statistical analysis of Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 191NCT00802841
• Learning Impairments Among Survivors of Childhood Cancer: Complete Statistical AnalysisIndependent statistical analysis of Learning Impairments Among Survivors of Childhood Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00576472).Phase 4Results postedn = 469NCT00576472
• LEMTRADA-ITPIndependent statistical analysis of Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 4Results postedn = 13NCT03784898
• Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00267059).Phase 2Results postedn = 45NCT00267059
• Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD): Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 5NCT00675441
• Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 30NCT01316523
• Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 49NCT01351896
• Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 8NCT02589145
• Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 33NCT00439231
• Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 77NCT00966693
• Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01380990).Phase 1/2Results postedn = 36NCT01380990
• Lesser Tuberosity Osteotomy for Subscapularis Repair: Complete Statistical AnalysisIndependent statistical analysis of Lesser Tuberosity Osteotomy for Subscapularis Repair: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02762903).Phase NAResults postedn = 60NCT02762903
• LIBERTY ASTHMA QUESTAn independent statistical analysis of the phase 3 LIBERTY ASTHMA QUEST trial of dupilumab 200 mg and 300 mg every two weeks versus matched placebo in persistent asthma, covering negative binomial rate…Phase 3Results postedn = 1,902NCT02414854
• LIDSIndependent statistical analysis of A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2/3Results postedn = 90NCT05276063
• Light Treatment to Improve Symptom Management of Fibromyalgia Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Light Treatment to Improve Symptom Management of Fibromyalgia Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03794908).Phase NAResults postedn = 60NCT03794908
• Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 54NCT02133664
• Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 48NCT01804101
• Liraglutide in Adolescents With Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Liraglutide in Adolescents With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02516657).Phase 3Results postedn = 5NCT02516657
• Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients: Complete Statistical AnalysisIndependent statistical analysis of Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 7NCT02481297
• Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006): Complete Statistical AnalysisIndependent statistical analysis of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03483103).Phase 2Results postedn = 74NCT03483103
• Living Well Project for Persons With AIDS: Complete Statistical AnalysisIndependent statistical analysis of Living Well Project for Persons With AIDS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01848483).Phase NAResults postedn = 121NCT01848483
• Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study: Complete Statistical AnalysisIndependent statistical analysis of Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 187NCT03733249
• Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 182NCT00811395
• Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer: Complete Statistical AnalysisIndependent statistical analysis of Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 395NCT00595517
• Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials – ECZTEND: Complete Statistical AnalysisIndependent statistical analysis of Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 1,672NCT03587805
• Long-term Open-Label Safety Study to Evaluate EN3409: Complete Statistical AnalysisIndependent statistical analysis of Long-term Open-Label Safety Study to Evaluate EN3409: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01755546).Phase 3Results postedn = 304NCT01755546
• Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 555NCT02462083
• Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 24NCT00527397
• Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2/3Results postedn = 302NCT01500551

← All therapeutic areas